Skip to content
PharmaVault

References and pharmacopoeiasمراجع و فارماکوپه‌ها

The pharmacopoeias, regulators and databases behind PharmaVault — with the edition in force today, the latest edition already published, and a direct link to each official source.

Editions last reviewed: October 2026. Links open the official site in a new tab. The full texts of USP–NF, BP, Ph. Eur. need a subscription; the others are free.

  1. 1

    United States Pharmacopeia – National Formulary

    USP–NF

    In force
    USP–NF 2026 — Issue 1 official 1 February 2026, Issue 2 on 1 April 2026, Issue 3 on 1 June 2026
    Next
    USP–NF 2027 issues, official from 2027

    The legal standard for medicines in the United States. Since 2026 USP–NF Online publishes several issues a year and every chapter or monograph carries its own official date, so check the “official” date of the text you cite.

    Official links

  2. 2

    British Pharmacopoeia

    BP

    In force
    BP 2026 — legally effective since 1 January 2026
    Latest published
    BP 2027 — available since 1 August 2026, legally effective 1 January 2027

    Published each August by the MHRA and legally effective from the following 1 January; it reproduces every Ph. Eur. monograph alongside about 4,000 monographs of its own.

    Official links

  3. 3

    European Pharmacopoeia

    Ph. Eur.

    In force
    12th Edition, Issue 12.3 — in force since 1 July 2026
    Latest published
    Issue 13.1 — published April 2026, in force 1 January 2027

    Published by the EDQM (Council of Europe) as three issues a year on an online-only platform; from Issue 13.1 the gap between publication and implementation is nine months. The old pheur.edqm.eu site was retired in January 2026.

    Official links

  4. 4

    Japanese Pharmacopoeia

    JP

    In force
    JP 19th Edition (JP19) — in effect since 10 April 2026, 2,072 monographs
    Next
    English translation of JP19 — usually within a year of publication

    Issued by the Ministry of Health, Labour and Welfare; PMDA drafts the monographs. JP is harmonised with USP and Ph. Eur. through the Pharmacopoeial Discussion Group (PDG).

    Official links

  5. 5

    US Food and Drug Administration

    FDA

    Approvals, guidance documents, excipient levels in approved products and recommended dissolution methods.

    Official links

  6. 6

    Orange Book

    Orange Book

    FDA's list of approved drug products with therapeutic-equivalence (TE) codes, reference listed drugs, patents and exclusivities — the starting point for generic development. Biologics are in the Purple Book.

    Official links

  7. 7

    DailyMed

    DailyMed

    The US National Library of Medicine's library of current package inserts (SPL): composition, inactive ingredients, storage and the full prescribing information, searchable by name, NDC or company.

    Official links

  8. 8

    European Medicines Agency

    EMA

    Centrally authorised medicines and their public assessment reports (EPAR), scientific guidelines and product-specific bioequivalence guidance for the EU.

    Official links

  9. 10

    ICH, PIC/S and international guidelines

    ICH · PIC/S

    In force
    Q1A(R2)–Q1E (consolidated Q1 still in draft), Q2(R2) and Q14 (2023), Q3C(R9) (2024), Q3D(R2) (2022), M7(R2) (2023), M4 (CTD)

    ICH sets the harmonised quality, safety and efficacy guidelines and the CTD format; PIC/S publishes the GMP guide followed by its member inspectorates.

    Official links